Stovickova, Lucie http://orcid.org/0000-0003-0646-0262
Hansikova, Hana http://orcid.org/0000-0002-2734-225X
Hanzalova, Jitka http://orcid.org/0000-0002-1024-7248
Musova, Zuzana
Semjonov, Valerij http://orcid.org/0009-0008-3966-7116
Stovicek, Pavel
Hadzic, Haris
Novotna, Ludmila http://orcid.org/0009-0006-9163-6486
Simcik, Martin
Strnad, Pavel
Serbina, Anastaziia
Karamazovova, Simona http://orcid.org/0009-0005-2279-474X
Schwabova Paulasova, Jaroslava http://orcid.org/0000-0002-8465-8269
Vyhnalek, Martin http://orcid.org/0000-0002-5976-4932
Krsek, Pavel http://orcid.org/0000-0002-5740-3690
Zumrova, Alena http://orcid.org/0009-0000-6586-3614
Funding for this research was provided by:
Grantová Agentura, Univerzita Karlova (309121, 226423)
EFACTS (NCT02069509)
Program EXCELES – Funded by the European Union – Next Generation EU (LX22NPO5107)
MH CZ – DRO (MH CZ-DRO-FNM64203, MH CZ-DRO-VFN64165)
Charles University
Article History
Received: 12 December 2023
Revised: 24 January 2024
Accepted: 24 January 2024
First Online: 23 March 2024
Declarations
:
: The authors declare that there are no conflicts of interest regarding the publication of this paper.
: This observational research project involved 41 Czech FA patients registered for baseline examination in the European Friedreich Ataxia Consortium for Translational Studies (EFACTS) registry (clinical trial.gov NCT02069509) from 07/2021 to 06/2022. Patient selection criteria included genetically confirmed FA, signed informed consent as approved by the ethics committee of Motol University Hospital and the Second Faculty of Medicine, Charles University (Approval No. EK-1340.19/20, dated 11/4/2020), and the ability to meet specific laboratory requirements for sample collection.